<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016275</url>
  </required_header>
  <id_info>
    <org_study_id>FMRP-007</org_study_id>
    <nct_id>NCT01016275</nct_id>
  </id_info>
  <brief_title>Misago Iliac Study</brief_title>
  <acronym>MISAGO ILIAC</acronym>
  <official_title>Physician Initiated Multi-center Belgian-German Trial Investigating the Terumo Misago Stent in the Treatment of TASC A &amp; B Iliac Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate, in a controlled setting, the long-term&#xD;
      (up to 24 months) outcome of the self-expanding nitinol rapid-exchange Misago (Terumo) stent&#xD;
      in TASC A and B iliac lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.0) and without Target Lesion Revascularization (TLR) within 12 months.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success, defined as the ability to achieve final residual angiographic stenosis no greater than 30%.</measure>
    <time_frame>procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.0) and without prior TLR are defined as being primary patent at the given follow-up.</measure>
    <time_frame>1 &amp; 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success, defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure Rutherford classification</measure>
    <time_frame>1, 12 &amp; 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vascular Lesions</condition>
  <arm_group>
    <arm_group_label>Iliac lesions TASC A or B</arm_group_label>
    <description>All lesion types belonging to the iliac TASC A or B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Misago (stent placement)</intervention_name>
    <description>Misago iliac stent</description>
    <arm_group_label>Iliac lesions TASC A or B</arm_group_label>
    <other_name>Misago iliac stent</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with peripheral arterial disease, Rutherford 2 to 5.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable&#xD;
             for stenting (on indication for primary stenting, based on the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Patient presenting a score from 2 to 5 following Rutherford classification&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times for the duration of the study&#xD;
&#xD;
          -  Patient is &gt;18 years old&#xD;
&#xD;
          -  Patient (or their legal representative) understands the nature of the procedure and&#xD;
             provides written informed consent, prior to enrolment in the study&#xD;
&#xD;
          -  Patient is eligible for treatment with the Misago (Terumo)&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class A or B lesion with one of the&#xD;
             listed specifications:&#xD;
&#xD;
               -  Type A lesions&#xD;
&#xD;
                    -  Unilateral or bilateral stenoses of the Common Iliac Artery&#xD;
&#xD;
                    -  Unilateral or bilateral single short (≤3 cm) stenosis of the External Iliac&#xD;
                       Artery&#xD;
&#xD;
               -  Type B lesions&#xD;
&#xD;
                    -  Unilateral Common Iliac Artery occlusion&#xD;
&#xD;
                    -  Single or multiple stenosis totaling 3-10 cm involving the External Iliac&#xD;
                       Artery not extending into the Common Femoral Artery&#xD;
&#xD;
                    -  Unilateral External Iliac Artery occlusion not involving the origins of&#xD;
                       Internal Iliac Artery or Common Iliac Artery&#xD;
&#xD;
          -  The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or&#xD;
             occlusion which can be passed with standard guidewire manipulation&#xD;
&#xD;
          -  There is angiographic evidence of a patent Common an Deep Femoral Artery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class B lesion with aortic lesion&#xD;
             involvement:&#xD;
&#xD;
               -  Short (≤3 cm) stenosis of infrarenal aorta&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class C or D lesion with aortic lesion&#xD;
             involvement:&#xD;
&#xD;
          -  Presence of aneurysm at the level of the iliac arteries&#xD;
&#xD;
          -  Previously implanted stent(s) at the same lesion site&#xD;
&#xD;
          -  Reference segment diameter is not suitable for available stent design&#xD;
&#xD;
          -  Untreatable lesion located at the distal outflow arteries&#xD;
&#xD;
          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation&#xD;
             therapy) as part of the index procedure&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
&#xD;
          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion&#xD;
             site&#xD;
&#xD;
          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
          -  Patients with a history of prior life-threatening contrast medium reaction&#xD;
&#xD;
          -  Patients with known hypersensitivity to nickel-titanium&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than twelve months&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow up period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Borovicanin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Terumo Europe NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerp</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <state>East-Flanders</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To obtain the first iliac long-term results for a patient cohort treated with nitinol stents only</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

